Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support

被引：4
|
作者：
Pennese, Elsa [1 ]
Vergine, Carolina [1 ]
Matera, Rosella [1 ]
Dargenio, Michela [1 ]
Forese, Pasquale [1 ]
Di Renzo, Nicola [1 ]
机构：
[1] Vito Fazzi Hosp, Hematol & Stem Cell Transplantat Unit, I-73100 Lecce, Italy
来源：
LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 11期
关键词：
PRIMARY CNS LYMPHOMAS; SALVAGE THERAPY; TEMOZOLOMIDE; CYTARABINE; ETOPOSIDE; TRIAL;
D O I：
10.3109/10428194.2011.585672
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2188 / 2189
页数：2
相关论文
共 48 条
  • [31] High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group
    Kasenda, B.
    Ihorst, G.
    Schroers, R.
    Korfel, A.
    Schmidt-Wolf, I.
    Egerer, G.
    von Baumgarten, L.
    Roeth, A.
    Bloehdorn, J.
    Moehle, R.
    Binder, M.
    Keller, U.
    Lamprecht, M.
    Pfreundschuh, M.
    Valk, E.
    Fricker, H.
    Schorb, E.
    Fritsch, K.
    Finke, J.
    Illerhaus, G.
    LEUKEMIA, 2017, 31 (12) : 2623 - 2629
  • [32] Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study
    Nakasu, Yoko
    Mitsuya, Koichi
    Hayashi, Nakamasa
    Okamura, Ikue
    Mori, Keita
    Enami, Terukazu
    Tatara, Raine
    Nakasu, Satoshi
    Ikeda, Takashi
    SPRINGERPLUS, 2016, 5
  • [33] Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
    Park, Jun Su
    Lim, Do Hoon
    Ahn, Yong Chan
    Park, Won
    Kim, Seok Jin
    Kim, Won Seog
    Kim, Kihyun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (11) : 995 - 1001
  • [34] A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
    Smeland, Knut B.
    Kiserud, Cecilie E.
    Lauritzsen, Grete F.
    Blystad, Anne K.
    Fagerli, Unn-Merete
    Falk, Ragnhild S.
    Fluge, Oystein
    Fossa, Alexander
    Kolstad, Arne
    Loge, Jon H.
    Maisenholder, Martin
    Ostenstad, Bjorn
    Kvaloy, Stein
    Holte, Harald
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (03) : 432 - 443
  • [35] Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM
    Devizzi, Liliana
    Guidetti, Anna
    Seregni, Ettore
    Passera, Roberto
    Maccauro, Marco
    Magni, Michele
    Testi, Adele
    Di Nicola, Massimo
    Tarella, Corrado
    Matteucci, Paola
    Viviani, Simonetta
    Ruella, Marco
    Carlo-Stella, Carmelo
    Chiesa, Carlo
    Cox, Maria Cristina
    Bombardieri, Emilio
    Gianni, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2974 - 2976
  • [36] Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study
    Vose, Julie M.
    Ganguly, Siddhartha
    Bierman, Philip J.
    Bociek, R. Gregory
    Lunning, Matthew
    Lyden, Liz
    Meza, Jane L.
    Caimi, Paolo F.
    Armitage, James O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (01) : 116 - 121
  • [37] High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity
    Seidel, Sabine
    Nilius-Eliliwi, Verena
    Kowalski, Thomas
    Ben Vangala, Deepak
    Schlegel, Uwe
    Schroers, Roland
    CANCERS, 2022, 14 (09)
  • [38] Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)
    Shah, N.
    Rauenzahn, S.
    Veltri, L.
    Wen, S.
    Craig, M.
    Hamadani, M.
    Kanate, A. S.
    Cumpston, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (02) : 321 - 322
  • [39] High-dose Busulfan and Cyclophosphamide as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Childhood Non-Hodgkin Lymphoma Patients: A Long-term Follow-up Study
    Andion, Maitane
    Molina, Blanca
    Gonzalez-Vicent, Marta
    Alonso, Laura
    Hernandez, Carmen
    Lassaletta, Alvaro
    Lopez-Ibor, Blanca
    Villa, Marta
    Angel Diaz, Miguel
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (03) : E89 - E91
  • [40] Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor
    Fergadis, Evangelos
    Gavrielatou, Niki
    Skouteris, Nikos
    Athanasopoulos, Aggelos
    Lianos, Evangelos
    Kosmas, Christos
    ANTI-CANCER DRUGS, 2019, 30 (02) : 205 - 208
12345